Provided by Tiger Trade Technology Pte. Ltd.

4D Molecular Therapeutics

9.18
-0.0350-0.38%
Volume:141.94K
Turnover:1.32M
Market Cap:524.21M
PE:-2.45
High:9.66
Open:9.52
Low:9.10
Close:9.21
52wk High:12.34
52wk Low:2.24
Shares:57.14M
Float Shares:40.87M
Volume Ratio:1.42
T/O Rate:0.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7446
EPS(LYR):-2.9821
ROE:-45.38%
ROA:-27.64%
PB:1.42
PE(LYR):-3.08

Loading ...

4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
2 hours ago

4D Molecular Therapeutics Reports Positive Interim Phase 1 Results for 4D-710 in Cystic Fibrosis

Reuters
·
Yesterday

4Dmt Announces Positive Interim Clinical Data From 4D-710 Aerow Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

THOMSON REUTERS
·
Yesterday

4D Molecular Therapeutics Grants 13,800 RSUs to New Employees Under Inducement Plan

Reuters
·
Dec 13

4D Molecular Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Kristian Humer, Chief Financial Officer

Reuters
·
Dec 12

4D Molecular Therapeutics to Present at J.P. Morgan Healthcare Conference

Reuters
·
Dec 08

Chief Legal Officer Scott Bizily Reports Disposal of 4D Molecular Therapeutics Inc. Common Shares

Reuters
·
Nov 20

4DMT Reports Long-Term Phase 1/2 Data Showing Durable Multi-Year Benefit of 4D-150 in Wet AMD

Reuters
·
Nov 20

Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Nov 18

Stock Track | 4D Molecular Therapeutics Soars 5.19% on Appointment of New CFO Kristian Humer

Stock Track
·
Nov 17

4D Molecular Therapeutics Names Kristian Humer as CFO

MT Newswires Live
·
Nov 17

4D Molecular names Kristian Humer as CFO

TIPRANKS
·
Nov 17

4Dmt Appoints Kristian Humer as Chief Financial Officer

THOMSON REUTERS
·
Nov 17

Press Release: 4DMT Appoints Kristian Humer as Chief Financial Officer

Dow Jones
·
Nov 17

4D Molecular Therapeutics Grants 45,400 RSUs to New Employees

Reuters
·
Nov 15

Institutional investors own a significant stake of 49% in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Simply Wall St.
·
Nov 12

Stock Track | 4D Molecular Therapeutics Soars 5.21% Amid Positive Analyst Updates

Stock Track
·
Nov 11

4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 11

Morgan Stanley Reaffirms Their Hold Rating on 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Nov 11

RBC Raises Price Target on 4D Molecular Therapeutics to $32 From $26, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Nov 11